Pomalidomide Myeloma Trials

Pomalidomide is a cancer medicine that promotes an immune response to help slow tumor growth. It is used in combination with dexamethasone to treat people with relapsed/refractory multiple myeloma who have received at least two prior medicines to treat their myeloma (including a type of medicine known as a proteasome inhibitor and lenalidomide).

SparkCures ID	5
Developed By	Celgene Corporation, a wholly owned subsidiary of Bristol Myers Squibb
Brand Name	Pomalyst^®
Generic Name	Pomalidomide
Additional Names	CC-4047, Actimid
Treatment Classifications	Immunomodulatory Drug (IMiD)

All Clinical Trials

View all active clinical trials around the US.

Verified

Phase 3 Clinical Trial comparing the use of venetoclax combined with dexamethasone versus Pomalidomide combined with dexamethasone in Relapsed/Refractory Mul...

CANOVA

View Trial

Verified

Study of Elranatamab (PF-06863135) Monotherapy and Elranatamab + Daratumumab Versus Daratumumab + Pomalidomide + Dexamethasone in Participants With Relapsed/...

MAGNETISMM-5

View Trial

Verified

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratum...

MAJESTEC-3

View Trial

Verified

Phase 3 Clinical Trial Comparing the Safety and Effectiveness of Selinexor, Pomalidomide and Dexamethasone vs Elotuzumab, Pomalidomide and Dexamethasone in R...

SELINEXOR

View Trial

Verified

Phase 3 Study Evaluating Subcutaneous vs Intravenous Isatuximab in Combination with Pomalidomide and Dexamethasone in Patients with Relapsed and/or Refractor...

IRAKLIA

View Trial

Verified

Phase 3 Clinical Trial Evaluating the Safety and Effectiveness of Investigational Drug Mezigdomide in Combination with Bortezomib and Dexamethasone Compared ...

SUCCESSOR-1

View Trial

Verified

Phase 3 Clinical Trial Comparing the Efficacy of an Investigational Medication Combined with Daratumumab or Daratumumab and Pomalidomide Versus Daratumumab, ...

MONUMENTAL-3

View Trial

Verified

Phase 1B Clinical Trial Studying the Safety, Activity, and Effectiveness of Cevostamab in Treating People with Relapsed or Refractory Multiple Myeloma

CAMMA-1

View Trial

Verified

A Phase III Study of Belantamab Mafodotin plus Pomalidomide and Dexamethasone vs Pomalidomide, Bortezomib and Dexamethasone in Participants with Relapsed / R...

DREAMM8

View Trial

Verified

Platform Study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination with Anti-Cancer Treatments in Participants with Relapsed/Refractory Mu...

DREAMM5

View Trial

Verified

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

View Trial

Verified

Multicenter, Open-label, Single-arm, Phase 1b/2 Study of the Safety and Efficacy of Combination Treatment With Pomalidomide, Dexamethasone, and Carfilzomib (...

View Trial

Verified

A Study of Belantamab Mafodotin in Combination With and Nirogacestat and Pomalidomide in People With Multiple Myeloma That Has Not Responded to Treatment or ...

View Trial

SparkCures Verified Accurate, up-to-date information. Learn more

Phase II Study of Belantamab Mafodotin in Combination With Carfilzomib, Pomalidomide, and Dexamethasone (KP...

BELANTAMAB MAFODOTIN

View Trial

A Phase II Study of ISABELA: Isatuximab, Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Relapsed ...

ISABELA

View Trial

Immunomodulatory Drugs (Lenalidomide With or Without Pomalidomide) in Combination With a Corticosteroid Dru...

MC210809

View Trial

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

View Trial

Study of Isatuximab Plus Pomalidomide and Dexamethasone in Highly Toxicity-vulnerable Subjects With Relapse...

View Trial

Marizomib Central Nervous System (CNS)

View Trial

Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multip...

View Trial

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

View Trial

Isatuximab, Carfilzomib, and Pomalidomide for the Treatment of Relapsed or Refractory Multiple Myeloma

View Trial

Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma

View Trial

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myelo...

D-CLAPD

View Trial

A Study of Daratumumab With Pomalidomide, Dexamethasone, and All-Transretinoic Acid in Patients With Multip...

View Trial

A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multipl...

SELINEXOR

View Trial

Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma

LEFLUNOMIDE

View Trial

A Study of Talquetamab With Other Anticancer Therapies in Participants With Multiple Myeloma

MONUMENTAL-2

View Trial

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-383 in C...

ABBV-383

View Trial

APG-2575 in Combination With Novel Therapeutic Regimens in Subjects With Relapsed or Refractory Multiple My...

APG-2575

View Trial

Ixazomib + Pomalidomide + Dexamethasone In Multiple Myeloma

View Trial

A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

IINNOVATE-2

View Trial

Selinexor, Pomalidomide, and Dexamethasone With or Without Carfilzomib for the Treatment of Patients With R...

SCOPE

View Trial

Myeloma-Developing Regimens Using Genomics

MYDRUG

View Trial

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments f...

LINVOSELTAMAB

View Trial

Untreated / Newly Diagnosed Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have been newly diagnosed or have not yet received treatment.